Related Experiment Video
Updated: Feb 26, 2026
08:56
Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
Published on: February 10, 2015
54.8K
Why Doesn't Primary Biliary Cholangitis Respond to Immunosuppressive Medications?
Antonio Molinaro1, Hanns-Ulrich Marschall1
1Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Sahlgrenska Academy, SE-413 45 Gothenburg, Sweden.
Current Hepatology Reports
|July 15, 2017
Summary
Immunosuppressive therapy has largely failed in Primary Biliary Cholangitis due to bile acid damage. Insufficient bicarbonate secretion hinders drug effectiveness, making treatments potentially harmful.
Area of Science:
- Hepatology
- Immunology
- Gastroenterology
Background:
- Primary Biliary Cholangitis (PBC) is a chronic liver disease characterized by autoimmune destruction of bile ducts.
- Current treatments for PBC often involve immunosuppressive and immunomodulatory therapies.
- The efficacy of these therapies in PBC has been limited, with some showing potential harm.
Purpose of the Study:
- To review and elucidate the reasons behind the historical failure of immunosuppressive therapy in Primary Biliary Cholangitis.
- To identify the underlying mechanisms that render immunosuppressive treatments ineffective or detrimental in PBC patients.
Main Methods:
- Systematic review of existing literature on immunosuppressive therapy in Primary Biliary Cholangitis.
- Analysis of preclinical and clinical studies investigating treatment outcomes and adverse effects.
- Evaluation of the role of bile acid metabolism and secretion in treatment response.
Main Results:
- Targeted immunosuppressive therapies have demonstrated limited efficacy and potential harm in PBC.
- Bile acid-mediated damage to cholangiocytes appears to be a significant factor.
- Insufficient bicarbonate secretion by cholangiocytes exacerbates bile acid toxicity.
Conclusions:
- Bile acid-mediated cholangiocyte damage, exacerbated by poor bicarbonate secretion, significantly undermines the therapeutic benefits of immunosuppressants in PBC.
- This mechanism attenuates the anti-inflammatory and anti-fibrotic effects of these drugs.
- Further research is needed to develop targeted therapies addressing bile acid dysregulation in PBC.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
604
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
604
01:29Inflammatory Bowel Disease IV: Pharmacological Management
852
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
852
01:29Chronic Pancreatitis II: Collaborative Care
433
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
433
01:17Chronic Bowel Disorders: Introduction
849
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
849
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
573
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
573
01:20Myasthenia Gravis: Overview and Treatment
3.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.1K